Results 91 to 100 of about 48,475 (244)

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial

, 2009
: Rapid bone loss and high rates of fractures occur following liver transplantation. To analyze the effect of intravenous pamidronate on bone loss after liver transplantation. A randomized, double-blind, placebo-controlled study was performed.
Casafont, F, Monegal, A, Guañabens, N, Suárez, MJ, De la Mata, M, Serrano, T, Barrios, C, Suárez, F, García-González, M, Clemente, G, Tome, S, Navasa, M.   +11 more
core   +1 more source

Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia

, 1992
We report the results of two consecutive randomized studies in the treatment of malignant hypercalcaemia with intravenous pamidronate. Overall normocalcaemia was achieved in greater than 90% of patients and a single infusion of 60 mg pamidronate given ...
Dodwell, D J, Howell, A; id_orcid, Morton, A R, Daley-Yates, P T, Hoggarth, C R   +4 more
core   +2 more sources

Clinical Evaluation of Onset of Analgesia Using Intravenous Pamidronate in Metastatic Bone Pain [PDF]

, 2002
Eugen Petcu, Stephan A. Schug, Homer W. Smith   +2 more
openalex   +1 more source

Non‐uraemic calciphylaxis successfully treated with pamidronate infusion [PDF]

, 2018
David Truong, Marcus M. Riedhammer, Kathya Zinszer   +2 more
openalex   +1 more source

Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations

, 2000
Up to 60% of patients receiving their first infusion of the bisphosphonate pamidronate experience an acute-phase reaction. In this study, we used flow cytometry to determine the effects of pamidronate treatment on circulating lymphocyte subpopulations ...
Sauty, A., Andrea Vera Keck, Martin Pecherstorfer, Zimmer-Roth, I., Keck, A. V., Eva Horn, Horn, E., Daniel Thiebaud, Ilse Zimmer-Roth, Jilch, R., Pecherstorfer, M., Ruth Jilch, Thiebaud, D., Alain Sauty   +13 more
core   +1 more source

Reversibility of Pamidronate-Associated Glomerulosclerosis [PDF]

, 2007
Meera Shreedhara, Andrew Z. Fenves, Diana Benavides, Marvin J. Stone   +3 more
openalex   +1 more source

Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis

, 2001
We examined the effect on bone mineral density (BMD) of a single dose of 3 mg/kg of the bisphosphonate, pamidronate (Novartis) in distraction osteogenesis in immature rabbits.
D. G. Little, C. T. Cowell, M. S. Cornell, C. M. Cooke-Yarborough, S. Arbuckle, J. Briody   +5 more
core   +1 more source

Short-Term, High-Dose Pamidronate-Induced Acute Tubular Necrosis: The Postulated Mechanisms of Bisphosphonate Nephrotoxicity

, 2003
A 76-year-old man had biopsy-proven acute tubular necrosis (ATN) after intravenous administration of 3 doses of 60 mg of pamidronate (Aredia) over a 2-week period. Pamidronate was given to treat hypercalcemia of unknown etiology.
Banerjee, Debasish, Roth, David, Preston, Richard A, Striker, Liliane, Asif, Arif, Bourgoignie, Jacques J   +5 more
core   +1 more source

Pamidronate induces modifications of circulating angiogenetic factors in cancer patients

, 2002
Purpose: Recently, new experimental data suggested that, besides inhibiting osteoclasts, bisphosphonate may also have an antitumor effect. Antiangionetetic activity is one of the possible mechanisms of anticancer activity attributed to bisphosphonates ...
Dicuonzo G, Denaro V, Battistoni F, Gavasci M, Avvisati G, Santini D, Vincenzi B, Salerno A, Tonini G   +8 more
core  

Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation [PDF]

, 2006
Andrew Grigg, Paul Shuttleworth, John Reynolds, AP Schwarer, Jeff Szer, Ken Bradstock, C. Hui, Richard Herrmann, Peter R. Ebeling   +8 more
openalex   +1 more source